Canaccord Genuity reissued their hold rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report issued on Friday. They currently have a $33.00 price target on the medical instruments supplier’s stock.
Several other research analysts also recently weighed in on the company. BidaskClub downgraded LeMaitre Vascular from a sell rating to a strong sell rating in a research note on Wednesday, December 27th. Benchmark downgraded LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday, October 27th. Zacks Investment Research downgraded LeMaitre Vascular from a buy rating to a hold rating in a research note on Wednesday, January 3rd. Stifel Nicolaus reaffirmed a buy rating on shares of LeMaitre Vascular in a research note on Sunday, October 29th. Finally, First Analysis downgraded LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 target price for the company. in a research note on Friday, October 27th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. LeMaitre Vascular presently has an average rating of Hold and a consensus target price of $33.00.
Shares of LeMaitre Vascular (NASDAQ LMAT) traded down $0.29 during trading hours on Friday, reaching $35.79. The company’s stock had a trading volume of 193,433 shares, compared to its average volume of 119,905. LeMaitre Vascular has a one year low of $21.36 and a one year high of $39.88. The firm has a market capitalization of $695.08, a P/E ratio of 42.11, a PEG ratio of 2.45 and a beta of 0.53.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The business had revenue of $26.15 million during the quarter, compared to the consensus estimate of $26.23 million. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 EPS. equities analysts expect that LeMaitre Vascular will post 0.98 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.78%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date is Wednesday, March 21st. LeMaitre Vascular’s dividend payout ratio is presently 25.88%.
Several hedge funds have recently made changes to their positions in LMAT. 361 Capital LLC purchased a new stake in shares of LeMaitre Vascular during the third quarter worth approximately $1,973,000. BNP Paribas Arbitrage SA increased its position in shares of LeMaitre Vascular by 97.6% during the third quarter. BNP Paribas Arbitrage SA now owns 7,405 shares of the medical instruments supplier’s stock worth $277,000 after purchasing an additional 3,657 shares in the last quarter. Allianz Asset Management GmbH increased its position in shares of LeMaitre Vascular by 4.7% during the third quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock worth $12,042,000 after purchasing an additional 14,306 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of LeMaitre Vascular by 4.4% during the second quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock worth $30,228,000 after purchasing an additional 40,767 shares in the last quarter. Finally, State Street Corp increased its position in shares of LeMaitre Vascular by 25.2% during the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock worth $11,951,000 after purchasing an additional 77,009 shares in the last quarter. 75.04% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/24/lemaitre-vascular-lmat-given-hold-rating-at-canaccord-genuity.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.